Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,557.34
(
-0.74%
)
US TECH 100
23,502.80
(
-0.92%
)
Dow Jones
45,823.43
(
-0.43%
)
Brent Oil
106.66
(
2.13%
)
Bitcoin
70,023.76
(
0.18%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 28533

Sunday, 05/14/2006 5:58:37 PM

Sunday, May 14, 2006 5:58:37 PM

Post# of 257262
COLY – the new phase-2 trials in of PF-3512676 in NSCLC are now on clinicaltrials.gov (link c/o TexasDude):

http://tinyurl.com/q49g3

So now we know that the new Tarceva and Alimta trials are in second-line NSCLC—the setting where Tarceva and Alimta are approved treatments—and the new Avastin trial is in non-squamous first-line NSCLC. The Avastin trial is restricted to non-squamous disease because Avastin has shown some troubling side effects in squamous patients.

PFE appears to be leaving no stone unturned in this program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today